Local therapy of cancer with free IL-2

Cancer Immunology, Immunotherapy

Volumn 57, Issue 7, 2008, Pages 931-950

  Den Otter, Willem ^a   Jacobs, John J L ^a   Battermann, Jan J ^b   Hordijk, Gerrit Jan ^b   Krastev, Zachary ^c   Moiseeva, Ekaterina V ^a,d   Stewart, Rachel J E ^e   Ziekman, Paul G P M ^a   Koten, Jan Willem ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c MEDICAL UNIVERSITY OF SOFIA   (Bulgaria)

^d SHEMYAKIN OVCHINNIKOV INSTITUTE OF BIOORGANIC CHEMISTRY   (Russian Federation)

^e UNIVERSITY OF ZIMBABWE   (Zimbabwe)

Author keywords

Bladder carcinoma; BOSCC; Immunotherapy; Interleukin 2; Nasopharyngeal carcinoma; Sarcoids

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; IFOSFAMIDE; IMIQUIMOD; INTERLEUKIN 2;

ADJUVANT THERAPY; ANTINEOPLASTIC ACTIVITY; BLADDER CARCINOMA; BLOOD VESSEL INJURY; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER SURGERY; CELL PROLIFERATION; COMBINATION CHEMOTHERAPY; CONCENTRATION (PARAMETERS); COUGHING; CYTOTOXICITY; DOSE RESPONSE; DRUG FORMULATION; DRUG RELEASE; EYE CANCER; FATIGUE; FEVER; FIBROSARCOMA; FRIEND LEUKEMIA; GASTROINTESTINAL TUMOR; HEART FAILURE; HISTOPATHOLOGY; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; KIDNEY CARCINOMA; LEUKOCYTE; LOCAL THERAPY; LUNG ALVEOLUS CELL CARCINOMA; LYMPHOMA; MELANOMA; MESOTHELIOMA; METASTASIS; MONOTHERAPY; NEOPLASM; NONHUMAN; OVARY CARCINOMA; PRIORITY JOURNAL; REVIEW; SARCOIDOSIS; SARCOMA; SENSITIVITY ANALYSIS; SINGLE DRUG DOSE; SQUAMOUS CELL CARCINOMA; SYSTEMIC THERAPY; TUMOR IMMUNITY; VASCULAR DISEASE; VASCULAR LEAKAGE SYNDROME;

ANIMALS; COMBINED MODALITY THERAPY; HUMANS; IMMUNOTHERAPY, ACTIVE; INTERLEUKIN-2; NEOPLASM METASTASIS; NEOPLASM TRANSPLANTATION; NEOPLASMS;

EID: 42649114787     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-008-0455-z     Document Type: Review

References (100)

1. Altman A, Theofilopoulos AN, Weiner R, Katz DH, Dixon FJ (1981) Analysis of T cell function in autoimmune murine strains. Defects in production and responsiveness to interleukin 2. J Exp Med 154:791-808
2. Anderson PM, Katsanis E, Leonard AS, Schow D, Loeffler CM, Goldstein MB, Ochoa AC (1990) Increased local antitumor effects of interleukin 2 liposomes in mice with MCA-106 sarcoma pulmonary metastases. Cancer Res 50:1853-1856
3. Antoni PA, Restifo NP (2005) CD4+CD25+ T regulatory cells, immunotherapy of cancer, and interleukin-2. J Immunother 28:120-128
4. Appleman LJ, Boussiotis VA (2003) T cell anergy and costimulation. Immunol Rev 162:161-180
5. Astoul P, Picat-Joossen D, Viallat JR, Boutin C (1999) Intrapleural administration of interleukin-2 for the treatment of patients with malignant pleural mesothelioma: a Phase II study. Cancer 86:546-547
6. Balemans LT, Steerenberg PA, Koppenhagen FJ, Kremer BH, De Mulder PHM, Claessen AM, Scheper RJ, Den Otter W (1994) PEG-IL-2 therapy of advanced cancer in the guinea pig. Impact of the primary tumor and beneficial effect of cyclophosphamide. Int J Cancer 58:871-876
7. Baluna R, Vitetta E (1997) Vascular leak syndrome: a side effect of immunotherapy. Immunopharmacology 37:117-132
8. Baselmans AHC, Koten JW, Battermann JJ, Van Dijk JE, Den Otter W (2002) The mechanism of regression of solid SL2 lymphosarcoma after local IL-2 therapy. Cancer Immunol Immunother 51:492-498
9. Basse PH (1995) Tissue distribution and tumor localisation of effector cells in adoptive immunotherapy of cancer. APMIS Suppl 55:1-28
10. Belardelli F, Ciolli V, Testa U, Montesoro E, Bulgarini D, Proietti E, Borghi P, Sestili P, Locardi P, Peschle C, et al. (1989) Anti-tumor effect of interleukin-2 and interleukin-1 in mice transplanted with different syngeneic tumors. Int J Cancer 44:1108-1116
11. Bendiksen S, Rekvig OP (2004) Interleukin-2, but not interleukin-15, is required to terminate experimentally induced clonal T-cell anergy. Scand J Immunol 60:64-73
12. Bernsen MR, Dullens HFJ, Den Otter W, Heinz APM (1995) Re-evaluation of the superiority of polyethylene glycol modified Interleukin-2 over regular recombinant IL-2. J Interferon and Cytokine Res 15:641-645
13. Bernsen MR, Tang J-W, Everse LA, Koten JW, Den Otter W (1999) Interleukin-2 (IL-2) therapy: potential advantages of locoregional versus systemic administration. Cancer Treatment Rev 25:73-82
14. Bernsen MR, Van der Velden AW, Everse LA, Dullens HFJ, Den Otter W, Heinz APM (1998) Interleukin-2: Hope in cases of Cisplatin resistant tumours. Cancer Immunol Immunother 6:41-47
15. Bubenik J, Indrova M (1987) The anti-tumour efficacy of human recombinant interleukin 2. Correlation between sensitivity of tumours to the cytolytic effect of LAK cells in vitro and their susceptibility to interleukin 2 immunotherapy in vivo. Cancer Immunol Immunother 24:269-271
16. Bubenik J, Indrova M, Perlmann P, Berzins K, Mach O, Kraml J, Toulcova A (1985) Tumour-inhibitory effects of TCGF (IL-2)-containing preparations. Cancer Immunol Immunother 9:57-61
17. Bubenik J, Kieler J, Indrova M (1986) Local treatment with human recombinant IL-2 inhibits growth of MC-induced sarcomas in syngeneic mice. Folia Biol (Praha) 32:209-211
18. Bubenik J, Perlmann P, Indrova M, Simova J, Jandlova T, Neuwirt J (1983) Growth inhibition of an MC-induced mouse sarcoma by TCGF (IL-2) containing preparations. Cancer Immunol Immunother 14:205-206
19. Burdin ML (1964) Squamous-cell carcinoma of the vulva in cattle in Kenia. Res Vet Sci 4:497-505
20. Cabanes A, Even-Chen S, Zimberoff J, Barenholz Y, Kedar E, Gabizon A (1999) Enhancement of antitumor activity of polyethylene glycol-coated liposomal doxorubicin with soluble and liposomal interleukin-2. Clin Cancer Res 5:687-693
21. Casana PH, Hernandez H, Arana MJ (2002) Interleukin-2 inhibits proliferation of HPV-associated tumor cells and halts tumor growth in vivo. Biochem Biophys Res Commun 299:818-824
22. Castagneto B, Zai S, Mutti L, Lazzaro A, Ridolfi R, Piccolini F, Ardizzoni A, Fumagalli L, Valsuani G, Botta M (2001) Palliative and therapeutic activity of IL-2 immunotherapy in unresectable malignant pleural mesothelioma with pleural effusion: results of a phase II study on 31 consecutive patients. Lung Cancer 31:303-310
23. Chi KH, Myers JN, Chow KC, Chan WK, Tsang YW, Chao Y, Yen SH, Lotze MT (2001) Phase II trial of systemic recombinant interleukin-2 in the treatment of refractory nasopharyngeal carcinoma. Oncology 60:110-115
24. De Mik HJI, Koten JW, Maas RA, Dullens HFJ, Den Otter W (1991) Tumour regression by IL-2 mediated stagnation of blood flow. In Vivo 5:679-684
25. Denekamp J (1984) Vascular endothelium as vulnerable element in tumours. Acta Radiol Oncol 23:217-225
26. Den Otter W et al (1998) Letter. J Urol 160:1808
27. Den Otter W, Balemans L, Battermann JJ, 17 other authors (1999) Local low-dose IL-2 therapy. Hepatogastroenterology 46(suppl.1):1280-1286
28. Den Otter W, Cadée J, Gavhumende R, De Groot CJ, Hennink WE, Stewart R (1999) Effective cancer therapy with a single injection of interleukin-2 at the site of the tumour. Cancer Immunol Immunother 48:419-420
29. Den Otter W, Dobrowolski Z, Bugajski A, Papla B, Van der Meijden APM, Koten JW, Boon TA, Siedlar M, Zembala M (1998) Intravesical IL-2 to treat T1 papillary carcinoma : regression of marker lesions in 8 out of 10 patients. J Urol 159:1183-1186
30. Den Otter W, Hill FWG, Klein WR, Koten JW, Steerenberg PA, De Mulder PHM, Rhode C, Stewart R, Faber JAJ, Rutten VPMG (1995) Therapy of bovine ocular squamous cell carcinoma with local doses of Interleukin-2 : 67% complete regressions after 20 months of follow-up. Cancer Immunol Immunother 41:10-14
31. Den Otter W, Hill FWG, Klein WR, Koten JW, Steerenberg PA, De Mulder PHM, Rutten VPMG, Ruitenberg EJ (1993) Low doses of interleukin-2 can cure large bovine ocular squamous cell carcinoma. Anticancer Res 13:2453-2455
32. Den Otter W, Steerenberg PA, Van der Laan JW (2002) Testing therapeutic potency of anticancer drugs in animal studies: a commentary. Regul Toxicol Pharmacol 35:266-272
33. Dubinett SM, Patrone L, Tobias J, Cochran AJ, Wen DR, McBride WH (1993) Intratumoral interleukin-2 immunotherapy: activation of tumor-infiltrating and splenic lymphocytes in vivo. Cancer Immunol Immunother 36:156-162
34. Edwards RP, Gooding W, Lembersky MC, Colonello K, Hammond R, Paradise C, Kowal CD, Kunschner AJ, Baldisser IM, Kirkwood JM, Herberman RB (1997) Comparison of toxicity and survival following intraperitoneal recombinant Interleukin-2 for persistent ovarian cancer after platinum: twenty-four-hour versus 7-day infusion. J Clin Oncol 15:3399-3407
35. Enk AH, Nashan D, Rubben A, Knop J (2000) High dose inhalation interleukin 2 therapy for lung metastases in patients with malignant melanoma. Cancer 2042-2046
36. Esteban-González E, Carballido J, Navas V, Torregrosa Z, Munoz A, de Mon MA, PortugueseSpanish Inhaled IL-2 Group (2007) Prospective review in patients with pulmonary metastases of renal cell carcinoma receiving inhaled recombinant interleukin-2. Anticancer Drugs 18:291-296
37. Everse LA, Bernsen MR, Dullens HFJ, Den Otter W (1996) The success of locoregional low-dose recombinant interleukin-2 (rIL-2) therapy in tumor-bearing mice is dependent on the time of rIL-2 administration. J Exp Ther Oncol 1:231-236
38. Everse LA, Renes B, Jürgenliemk-Schulz IM, Rutgers DH, Bernsen MR, Dullens HFJ, Den Otter W, Battermann JJ (1997) Local low-dose interleukin-2 induces systemic immunity when combined with radiotherapy of cancer. A pre-clinical study. Int J Cancer 72:1003-1007
39. Fasler S, Aversa G, Terr A, Thestrup-Pedersen K, de Vries JE, Yssel H (1995) Peptide-induced anergy in allergen-specific human Th2 cells results in lack of cytokine production and B cell help for IgE synthesis. Reversal by IL-2, not by IL-4 or IL-13. J Immunol 155:4199-4206
40. Ferlazzo G, Magno C, Iemmo R, Rizzo M, Lupo G, Semino C, Bruno S, Melioli G (1996) Treatment of superficial bladder cancer with intravesical perfusion of rIL-2: a follow-up study. Anticancer Res 16:979-980
41. Ferlazzo G, Magno C, Lupo G, Rizzo M, Iemmo R, Semino C, Melioli G (1995) A phase I study of intravesical continuous perfusion of recombinant interleukin-2 in patients with superficial bladder cancer. Am J Clin Oncol 16:100-104
42. Fiszer-Maliszewska L, Den Otter W, Mordarski M (1999) Effect of local interleukin-2 treatment on spontaneous tumours of different immunogenic strength. Cancer Immunol Immunother 47:306-314
43. Goey SH, Eggermont AM, Punt CJ, Slingerland R, Gratama JW, Oosterom R, Oskam R, Bolhuis RL, Stoter G (1995) Intrapleural administration of interleukin-2 in pleural mesothelioma: a phase I-II study. Br J Cancer 72:1283-1288
44. Gomella LG, McGinnis DE (1998) Letter to the Editor. Urology 160:1808
45. Gomella LG, McGinnis DE, Baltish MA, Thompson I, Butler K, Marshall E (1993) Treatment of superficial transitional cell carcinoma of the bladder with recombinant interleukin-2 (rIL-2) (CETUS). Cancer Biother 8:223-227
46. Grande C, Firvida JL, Navas V, Casal J (2006) Interleukin-2 for the treatment of solid tumors other than melanoma and renal cell carcinoma. Anticancer Drugs 17:1-12
47. Grasso M, Torelli F, Scannapieco G, Franzoso F, Lania C (2001) Neoadiuvant treatment with intravesical Interleukin-2 for recurrent superficial transitional bladder carcinoma Ta-T1/G1-2. J Immunother 24:184-187
48. Green DS, Bodman-Smith MD, Dalgleish AG, Fischer MD (2007) Phase I/II study of topical imiquinod and intralesional interleukin-2 in the treatment of accessible metastases in malignant melanoma. Br J Dermatol 156:337-345
49. Gregoriadis G, Poste G (1984) Drug targeting in cancer therapy. In: Senior J, Trouet A (eds), Receptor-mediated targeting of drugs. Plenum Press, New York, pp 448-451
50. Hautmann SH, Huland E, Huland H (1999) Local intratumor immunotherapy of prostate cancer with interleukin-2 reduces tumor growth. Anticancer Res 19:2661-2663
51. Hill FWG, Klein WR, Hoyer HJ, Rutten VPMG, Kock N, Steerenberg PA, Ruitenberg EJ, Den Otter W (1994) Antitumor effect of locally injected low doses of recombinant human interleukin-2 in bovine vulval papilloma and carcinoma. Vet Immunol Immunopathol 41:19-29
52. Huland E, Heinzer H, Mir TS, Huland H (1997) Inhaled interleukin-2 therapy in pulmonary metastatic renal cell carcinoma. Cancer J Sci Am 3(Suppl 1):S98-S105
53. Huland E, Huland H (1989) Local continuous high dose interleukin 2: a new therapeutic model for the treatment of advanced bladder carcinoma. Cancer Res 49:5469-5474
54. Indrova M, Bubenik J, Mikyskova R, Mendoza L, Simova J, Bieblova J, Jandlova T, Jinoch P, Smahel M, Vonka V, Pajtasz-Piasecka E (2003) Chemoimmunotherapy in mice carrying HPV16-associated, MHC class I+ and class I- tumours: Effects of CBM-4A potentiated with IL-2, IL-12, GM-CSF and genetically modified tumour vaccines. Int J Oncol 22:691-695
55. Jacobs JJL, Hordijk GJ, Jürgenliemk-Schulz IM, Terhaard CHJ, Koten JW, Battermann JJ, Den Otter W (2005) Treatment of stage III-IV nasopharyngeal carcinomas by external beam irradiation and local low doses of IL-2. Cancer Immunol Immunother 54:792-798
56. Jacobs JJL, Sparendam D, Den Otter W (2005) Local interleukin-2 therapy is therapeutically more effective against cancer when injected intratumourally. Cancer Immunol Immunother 54:647-654
57. Janssen RA, Mulder NH, The TH, de Leij L (1994) The immunobiological effects of interleukin-2 in vivo. Review. Cancer Immunol Immunother 39:207-216
58. Jürgenliemk-Schulz IM, Renes IB, Rutgers DH, Everse LA, Bernsen MR, Den Otter W, Battermann JJ (1997) Anti-tumor effects of local irradiation in combination with peritumoral administration of low doses of recombinant interleukin-2 (rIL-2). Radiat Oncol Investig 5:54-61
59. Kaplan B, Moy RL (2000) Effect of perilesional injections of PEG-interleukin-2 on basal cell carcinoma. Dermatol Surg 26:1037-1040
60. Koten JW, Van Luyn MJA, Cadée JA, Brouwer L, Hennink WE, Bijleveld C, Den Otter W (2003) IL-2 loaded dextran microspheres with attractive histocompatibility properties for local IL-2 cancer therapy. Cytokine 24:57-66
61. Krastev Z, Koltchakov C, Tomova R, Deredjian S, Alexiev A, Popov D, Tomov B, Koten JW, Jacobs J, Den Otter W (2005) Locoregional IL-2 low dose application for gastrointestinal tumors. World J Gastroenterol 11:5525-5529
62. Krastev Z, Koltchakov V, Vladov N, Popov D, Milev A, Koten JW, Den Otter W (2001) A mesothelioma that is sensitive to locally applied IL-2. Cancer Immunol Immunother 50:226-227
63. Kubo T, Hatton RD, Oliver J, Liu X, Elson CO, Weaver CT (2004) Regulatory T cell suppression and anergy are differentially regulated by proinflammatory cytokines produced by TLR-activated dendritic cells. J Immunol 173:7249-7258
64. Kusnierczyk H, Pajtasz-Piasecka E, Koten JW, Bijleveld C, Krawczyk K, Den Otter W (2004) Further development of local IL-2 therapy of cancer: multiple versus single IL-2 treatment of transplanted murine colon carcinoma. Cancer Immunol Immunother 53:445-452
65. Lissoni P, Barni S, Ardizzoia A, Paolorossi F, Tisi E, Crispino S, Tancini G (1992) Intracavitary administration of interleukin-2 as palliative therapy for neoplastic effusions. Tumori 78:118-120
66. Liu CM, Suzuki Y, Chen LP, Okayasu T, Calkins CE, Wheelock EF (1990) Maintenance and cure of the L5178Y murine tumor-dormant state by interleukin-2: in vivo and in vitro effects. Cancer Res 50:1361-1367
67. Maas RA, Dullens HFJ, De Jong WH, Den Otter W (1989) Immunotherapy of mice with a large burden of disseminated lymphoma with low-dose interleukin-2. Cancer Res 49:7037-7040
68. Maas RA, Van Weering DHJ, Dullens HFJ, Den Otter W (1991) Intratumoral low-dose interleukin-2 induces rejection of distant solid tumour. Cancer Immunol Immunother 33:389-394
69. Maekawa R, Matsumoto M, Kitagawa T, Harada M, Sato K (1986) Effect of recombinant IL-2 (R-IL-2) on in vivo growth of murine myeloma X5563. Cancer Immunol Immunother 23:25-30
70. Margolin KA (2000) Interleukin-2 in the treatment of renal cancer. Semin Oncol 27:194-203
71. Masotti A, Fumagalli L, Morandini GC (1997) Intrapleural administration of recombinant interleukin-2 in non-small cell lung cancer with neoplastic pleural effusion. Monaldi Arch Chest Dis 52:225 228
72. Mattijssen V, Balemans LTM, Steerenberg PA, De Mulder PHM (1992) Polyethylene-glycol-modified interleukin-2 is superior to interleukin-2 in locoregional immunotherapy of established guinea pig tumours. Int J Cancer 51:812-817
73. Moiseeva EV, Merkulova IB, Bijleveld C, Koten JW, Miroshnikov AI, Den Otter W (2003) Therapeutic effect of a single dose of IL-2 on transplanted murine breast cancer. Cancer Immunol Immunother 52:487-496
74. Munger W, Dejoy SQ, Wick MM, Kerwar SS (1995) Studies on evaluating the antitimour acticity and toxicity of interleukin-15, a new T cell growth factor: comparison with interleukin-2. Cell Immunol 165:289-293
75. Nelson BH (2004) IL-2 regulatory T cells, and tolerance. J Immunol 172:3983-3988
76. Onizuka S, Tawara I, Shimizu J, Sakaguchi S, Fujita T, Nakayama E (1999) Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. Cancer Res 59:3129-3133
77. Onodera K, Volk HD, Ritter T, Kupiec-Weglinski JW (1998) Thymus requirement and antigen dependency in the "Infectious" tolerance pathway in transplant recipients. J Immunol 160:5765-5772
78. Pfohler C, Steinhauser S, Wagner A, Ugurel S, Tilgen W (2004) Complete remission of cutaneous satellite and in-transit metastases. After intralesional therapy with interleukin-2 in 2 patients with malignant melanoma Hautarzt. 55:171-175 (Article in German)
79. Pizza G, Severini G, Menniti D, De Vinci C, Corrado F (1984) Tumour regression after intralesional injection of interleukin-2 (IL-2) in bladder cancer. Preliminary report. Int J Cancer 34:359-367
80. Radny P, Caroli UM, Bauer J, Paul T, Schlegel C, Eigentler TK, Weide B, Schwartz M, Garbe C (2003) Phase II trial of intralesional therapy with interleukin-2 in soft tissue melanoma metastases. Br J Cancer 89:1620-1626
81. Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghausen SE, Matory YL, Skibber JM, Shiloni E, Vetto JT, Seipp CA, Simpson C, Reichert CM (1985) Observations on the systemic administration of autologous lymphokine activated killer cells and recombinant IL-2 to patients with metastatic cancer. New Engl J Med 313:1485-1492
82. Rosenberg SA, Mulé, Spiess PJ, Reichert CM, Schwarz SL (1985) Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin-2. J Exp Med 161:1169-1188
83. Rosenstein M, Ettinghausen SE, Rosenberg SA (1986) Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin 2. J Immunol 137:1735-1742
84. Rutten VPMG, Klein WR, De Jong WAC, Misdorp W, DenOtter W, Steerenberg PA, De Jong WH, Ruitenberg EJ (1989) Local IL-2 therapy in bovine ocular squamous cell carcinoma. A pilot study. Cancer Immunol Immunother 30:165-169
85. Shirai M, Watanabe S, Nishioka M (1990) Antitumour effect of intratumoral injection of human recombinant interleukin-2 in patients with hepatocellular carcinoma: a preliminary report. Eur J Cancer 26:1045-1048
86. Silagi S, Schaefer AE (1986) Successful immunotherapy of mouse melanoma and sarcoma with recombinant interleukin-2 and cyclophosphamide. J Biol Resp Mod 5:411-422
87. Sosnovski JT, DeHaven JI, Riggs DR, Lamm DL (1991) Treatment of murine transitional cell carcinoma with intralesional interleukin-2 and murine interferon gamma. J Urol 146:1164-1167
88. Spoormakers TJP, Klein WR, Jacobs JJL, Van den Ingh ThSGAM, Koten JW, Den Otter W (2003) Comparison of the local treatment of equine sarcoids with IL-2 or cisplatin/IL-2. Cancer Immunol Immunother 52:179-184
89. Stewart RJE, Hill FWG, Masztalerz A, Jacobs JJL, Koten JW, Den Otter W (2006) Treatment of ocular squamous cell carcinomas in cattle using interleukin-2. Vet Rec 159:668-672
90. Stewart RJE, Masztalerz A, Jacobs JJL, Den Otter W (2005) Local interleukin-2 and interleukin-12 therapy of bovine ocular squamous cell carcinomas. Vet Immunol Immunopathol 106:277-284
91. Taylor DD, Edwards RP, Case CR, Gercel-Taylor C (2004) Modulation of CD3-zeta as a marker of clinical response to IL-2 therapy in ovarian cancer patients. Gynecol Oncol 94:54-60
92. Tomova R, Pomakov J, Jacobs JJL, Adjarov D, Popova S, Altankova I, Den Otter W, Krastev Z (2006) Changes in cytokine profile during local IL-2 therapy in cancer patients. Anticancer Res 26:2037-2047
93. Tubaro A, Stoppacciaro A, Velotti F, Bossola PC, Cusumano G, Vicentini C, De Carli P, Ruco L, Santoni A, Cancrini A, et al. (1995) Local immunotherapy of superficial bladder cancer by intravesical instillation of recombinant interleukin 2. Eur Urol 28:297-303
94. Vaage J (1987) Local and systemic effects during interleukin-2 therapy of mouse mammary tumors. Cancer Res 47:4296-4298
95. Vaage J (1991) Peri-tumor interleukin-2 causes systemic therapeutic effect via interferon-gamma induction. Int J Cancer 49:598-600
96. Van Es R, Baselmans AHC, Koten JW, Van Dijk JE, Koole R, Den Otter W (2000) Perilesional IL-2 treatment of a VX2 head and neck cancer model can induce a systemic anti-tumour activity. Anticancer Res 20:4163-4170
97. Vlock DR, Snyderman CH, Johnson JT, Myers EN, Eibling DE, Rubin JS, Kirkwood JM, Dutcher JP, Adams GL (1994) Phase Ib trial of the effect of peritumoral and intranodal injections of interleukin-2 in patients with advanced squamous cell carcinoma of the head and neck: an Eastern Cooperative Oncology Group trial. J Imunother Emphasis Tumor Immunol 15:134-139
98. Wiig H (1982) Microvascular pressures in DMBA-induced rat mammary tumors. Scand J Clin Lab Invest 42:165-171
99. Yu P, Lee Y, Liu W, Krausz T, Chong A, Schreiber H, Fu YX (2005) Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors. J Exp Med 201:779-791
100. Ziekman PGPM (1999) Local low-dose IL-2 therapy of tumours in companion animals. Anticancer Res 19:1995